What is SphingoTec?
Headquartered at the intersection of biotechnology and clinical diagnostics, SphingoTec specializes in the identification and validation of novel biomarkers for life-threatening conditions such as sepsis, acute kidney injury, and heart failure. By providing clinicians with rapid, precise diagnostic data, the company facilitates more effective patient monitoring and personalized treatment strategies. Their business model relies on a robust pipeline of IVD assays developed in collaboration with global medical centers and pharmaceutical partners, positioning them as a critical player in the evolving landscape of precision medicine and acute care management.
How much funding has SphingoTec raised?
SphingoTec has raised a total of $21.6M across 2 funding rounds:
Private Equity
$16.1M
Series C
$5.5M
Private Equity (2018): $16.1M with participation from Wellington Partners and HBM Healthcare Investments
Series C (2024): $5.5M led by Brandenburg Kapital, Think.Health Ventures, and HBM Healthcare Investments
Key Investors in SphingoTec
HBM Healthcare Investments
A publicly traded investment firm focused on the global healthcare sector, targeting value creation through a diversified portfolio of private and public life science companies.
Wellington Partners
A leading European venture capital firm specializing in early- and growth-stage life science companies, including diagnostics and medical devices.
Brandenburg Kapital
The most active equity investor in Brandenburg, providing capital to technology-oriented companies across the life science and MedTech sectors.
What's next for SphingoTec?
With this major enterprise-level funding, SphingoTec is well-positioned to accelerate its commercialization efforts and expand its diagnostic portfolio. The strategic focus will likely shift toward scaling the adoption of its proprietary assays within international critical care markets and deepening its collaborative research initiatives. By leveraging this capital, the company aims to solidify its market position, enhance its diagnostic capabilities, and ultimately improve patient outcomes in high-acuity settings, ensuring long-term growth and sustained innovation in the healthcare sector.
See full SphingoTec company page
